Published in final edited form as:

Ophthalmology. 2020 November ; 127(11): 1549–1557. doi:10.1016/j.ophtha.2020.05.024.

Recommendations for long-term follow-up of adults with heritable retinoblastoma

Emily S. Tonorezos, MD MPH,

Memorial Sloan Kettering and Weill Cornell Medical College, New York, New York, USA

Danielle Novetsky Friedman, MD MS,

Memorial Sloan Kettering, New York, New York, USA

Dana Barnea, MD,

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Machteld I. Bosscha, MD,

Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Guillermo Chantada, MD,

Hospital Juan P. Garrahan, Buenos Aires, Argentina

Charlotte J. Dommering, MD, PhD,

Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Pim de Graaf, MD PhD,

Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

Ira J. Dunkel, MD,

Memorial Sloan Kettering and Weill Cornell Medical College, New York, New York, USA

Armida W.M. Fabius, PhD,

Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Jasmine H. Francis, MD,

Memorial Sloan Kettering, New York, New York, USA

Mary-Louise C. Greer, MBBS,

Hospital for Sick Children, University of Toronto, Toronto, Canada

Ruth A. Kleinerman, MPH PhD,

Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

Corresponding author: Emily Tonorezos, MD MPH, Memorial Sloan Kettering and Weill Cornell Medical Center, 485 Lexington Ave, 2nd Floor, New York, NY 10017, T 646-888-8080; F 929-321-1518, tonoreze@mskcc.org.

*Co-senior author

Contributions: Concept: ET, DF, ID, KO, DA; literature search: ET, DB. All authors participated in the data analysis, data interpretation, in-person meeting in New York City, as well as drafting and editing of the manuscript.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of interest: None.

Wijnanda A. Kors, MD,

Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Suzanne Laughlin, MD,

Hospital for Sick Children, University of Toronto, Toronto, Canada

Annette C. Moll, MD PhD,

Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Lindsay M. Morton, PhD,

Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

Petra Temming, MD,

Essen University, Essen, Germany

Margaret A. Tucker, MD,

Division of Cancer Epidemiology & Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

Flora E. van Leeuwen, PhD,

Netherlands Cancer Institute, Amsterdam, The Netherlands

Michael F. Walsh, MD,

Memorial Sloan Kettering, New York, New York, USA

Kevin C. Oeffinger, MD*,

Duke University, Durham, North Carolina, USA

David H. Abramson, MD*

Memorial Sloan Kettering and Weill Cornell Medical College, New York, New York, USA

Abstract

Objective: Generate recommendations for long-term follow-up for adult survivors of heritable retinoblastoma.

Design: We convened a meeting of providers from retinoblastoma centers around the world to review the state of the science and to evaluate the published evidence.

Subjects: Retinoblastoma is a rare childhood cancer of the retina. Approximately forty percent of retinoblastoma cases are heritable, due to a germline mutation in *RBI*. Dramatic improvements in treatment and supportive care have resulted in a growing adult survivor population. Survivors of heritable retinoblastoma, however, have significantly increased risk of subsequent malignant neoplasms, particularly bone and soft tissue sarcomas, uterine leiomyosarcoma, melanomas, and radiotherapy-related central nervous system tumors, which are associated with excess morbidity and mortality. In spite of these risks, no surveillance recommendations for this population are currently in place and surveillance practices vary widely by center.

Methods: Following the Institute of Medicine procedure for clinical practice guideline development, a PubMed, EMBASE, and Web of Science search was performed, resulting in 139 papers; after abstract and full text review, 37 papers underwent detailed data abstraction to

quantify risk and evidence regarding surveillance, if available. During an in-person meeting, evidence was presented and discussed, resulting in consensus recommendations.

Main outcome measures: Diagnosis and mortality from subsequent neoplasm.

Results: While evidence for risk of subsequent neoplasm, especially sarcoma and melanoma, was significant, evidence supporting routine testing of asymptomatic survivors was not identified. Skin examination for melanoma and prompt evaluation of signs and symptoms of head and neck disease were determined to be prudent.

Conclusions: This review of the literature confirmed some of the common second cancers in retinoblastoma survivors, but found little evidence for a benefit to currently available surveillance for these malignancies. Future research should incorporate international partners, patients, and family members.

Precis

We convened an international meeting to review evidence for long-term follow-up of retinoblastoma survivors. Risk for subsequent neoplasm, notably sarcoma and melanoma, is significant. Yet, no studies demonstrate benefit of radiologic testing in asymptomatic survivors.

Keywords

guidelines; magnetic resonance imaging; melanoma; osteosarcoma; pineoblastoma; retinoblastoma; sarcoma; survivorship; subsequent malignant neoplasm; trilateral retinoblastoma

INTRODUCTION

Retinoblastoma (RB) is a rare childhood cancer of the retina. Survival from RB has increased dramatically over the past decades and currently exceeds 95% in resource-rich settings.^{1–4} Approximately forty percent of RB cases are heritable, carrying a germline mutation in *RBI*, and frequently develop bilateral RB. Survivors of heritable RB, especially those who received external beam radiotherapy, have significantly increased risk of developing subsequent malignant neoplasms (SMN).^{5, 6} Commonly described SMN include bone and soft tissue sarcomas, malignant melanomas, and radiotherapy-related central nervous system tumors; SMN are associated with excess morbidity and mortality. Among other childhood cancer survivors, SMN risk and appropriate surveillance (testing asymptomatic survivors) have been identified.^{6, 7, 8} Despite these risks, SMN surveillance for adults with a history of heritable RB varies widely based on local practices, and no guidelines are currently available.

In recognition of these discrepancies, we convened a meeting of specialists from RB centers around the world to review the state of the science and evaluate the published evidence in the Spring of 2017. This international interdisciplinary panel included ocular oncologists, epidemiologists, survivorship specialists, pediatric oncologists, radiologists, and a geneticist. The objective of the meeting was to develop evidence- and consensus-based international SMN surveillance guidelines for survivors of heritable RB, using standardized guideline-writing practices.^{6, 9–12} In preparation for the meeting, we created a Delphi process for generating the meeting agenda, as in other guideline development settings.^{13–16} Potential

SMN sites to be reviewed were circulated to the attendees, who anonymously indicated their priorities for discussion. After review of these submissions, the list of SMNs to be reviewed was generated and a literature search for relevant studies was conducted. Notably, as the guidelines are intended to adults (those over the age of 18) with a history of heritable RB, pinealoblastoma or trilateral blastoma, and surveillance for recurrent disease, were excluded from discussion.

An English language PubMed, EMBASE, and Web of Science search was performed to identify all relevant literature. Keywords and medical subject heading terms were used to identify potentially relevant titles and abstracts. Search terms included “retinoblastoma,” “neoplasms, second primary,” “mass screening,” “population surveillance,” and “follow up.” Details of the search and the selection of papers for data abstraction are reported in the Appendix. Initially, 139 papers were identified. After evaluation by two authors (ET and DB), 37 manuscripts were selected for data abstraction. Attendees were assigned SMN sites for abstraction and received the relevant manuscripts for review prior to the meeting.

On the meeting day, participants presented the abstracted data. Evidence for the magnitude of risk and of the benefits and harms associated with SMN surveillance was reviewed and graded using National Comprehensive Cancer Network (NCCN) Categories of Evidence and Consensus, which is the standard method for grading the evidence in developing NCCN guidelines across cancer types.^{17, 18, 19} Recommendations were drafted and circulated to the attendees, with continued revision and clarification, as well as supplemental literature searches, where helpful. The Memorial Sloan Kettering Institutional Review Board approval was not required for this work.

Recommendations for long-term follow-up of adults with heritable RB, developed as a result of this process are presented here, with quality of evidence and strength of recommendation gradings. Surveillance recommendations for SMN (in alphabetical order) are summarized in Table 1 and presented in detail below.

EVIDENCE REVIEW

Bone and soft tissue sarcoma

Evidence of risk: Yes

Grade of evidence for risk: A

Recommendation for surveillance: Recommendation not to do

Among all SMN subtypes, survivors of heritable RB are at highest risk for subsequent bone and soft tissue sarcoma.^{20–34} We reviewed 32 publications, including 28 that reported the results of cohort studies and 4 case reviews or clinical series, describing subsequent sarcoma in heritable RB survivors.^{1,14,20,22–24,26–29,32–53} In an analysis of subsequent malignancy risk in 963 one-year RB survivors with heritable disease diagnosed between 1914 and 1984, survivors were found to be at highest risk for subsequent cancers of the bone (standardized incidence ratio [SIR] 360, 95% confidence interval [CI] 283–451), predominantly osteosarcoma, and connective and soft tissue (SIR 122, 95% CI: 84–170).³² Very high risks

have been identified for a variety of soft tissue subtypes, including fibrosarcomas, rhabdomyosarcomas, and malignant fibrous histiocytomas, as well as late-onset leiomyosarcomas.²³ Risk is particularly pronounced among those with prior radiotherapy and systemic chemotherapy exposure;^{26, 27, 29, 32, 44, 46} several reports have demonstrated even higher risk among those irradiated in the first year of life.^{54–56}

In addition to radiotherapy -related risk, heritable RB survivors are also at risk for sarcomas of bone and soft tissue outside the field of radiotherapy^{22, 23, 32} and in the absence of any history of radiotherapy,^{23, 33} thus underscoring a genetic predisposition to sarcomas independent of radiation exposure. Note that further information about uterine tumors (predominantly leiomyosarcomas) is provided below in a separate section. Recent reports have suggested that risk may be attenuated in the presence of specific genetic alterations³⁹ and/or after treatment with proton radiotherapy^{52, 57} but further research is required to confirm these findings.

In some institutions, it is common practice to periodically image the head and neck region of RB survivors. We found no studies that quantified the potential benefits of such surveillance practices. In addition, there has been much enthusiasm about the use of surveillance whole-body magnetic resonance imaging (whole-body MRI) for patients with genetic predisposition syndromes.^{58–61} One study demonstrated the feasibility of performing these studies in heritable RB survivors,⁴¹ but the analysis was limited by small sample size and retrospective design. Given these limited data, our panel does not recommend annual whole-body or regional MRI surveillance in heritable RB survivors. This recommendation is based on a preliminary lack of evidence for benefit coupled with concern for possible harms, including: the need for additional testing after false positives; potential for gadolinium deposition, although whole-body MRI is often performed without contrast;^{62, 63} and increased testing-related anxiety and/or psychosocial distress.⁶⁴ Based on the experience with other predisposition syndromes, however, it could be worthwhile to formally open an international prospective surveillance trial to delineate the utility of this test.

Therefore, in accord with the recent consensus guidelines from the American Association for Cancer Research (AACR) Childhood Cancer Predisposition Workshop,⁶⁵ our multidisciplinary panel recommends an annual comprehensive history and physical exam, with an emphasis on educating adult patients and families about concerning signs and symptoms (Table 1). Heritable RB survivors should receive prompt medical evaluation for any new concerns. However, routine surveillance for bone and soft tissue sarcoma with whole-body MRI, MRI of the head and neck, or other imaging modalities in asymptomatic heritable RB survivors is not recommended.

Brain and central nervous system

Evidence of risk: Yes

Grade of evidence for risk: A

Recommendation for surveillance: Recommendation not to do

We reviewed 21 papers including 20 cohort studies and 1 case series that reported the risk of CNS tumors (excluding pineoblastoma or trilateral RB) among heritable RB survivors.^{1, 14, 22, 262829, 32–37, 45, 46, 48, 50–53, 66, 67} Radiotherapy-related CNS tumors are well-known sequelae following radiotherapy for childhood tumors,^{68, 69} as reflected in these studies. In a cohort of 963 survivors of heritable RB treated in the United States, 10 cases of CNS tumors were described, resulting in a SIR of 3.96 (95% CI: 1.9-7.3);³² no CNS tumors were observed among heritable RB survivors who did not receive radiotherapy (SIR = 0.0; 95%CI: 0-33). Notably, in a recent paper describing SMN risk in 55 RB survivors treated with proton radiotherapy and followed for a median of 6.9 years (range 1-24), no subsequent CNS tumors were observed.⁵² However, given the small size of this sample and the relatively short reported follow-up, there is insufficient evidence to draw definite conclusions about subsequent malignancy risk after proton beam therapy. Furthermore, no study has demonstrated a benefit of routine CNS surveillance in RB survivors with or without a history of radiotherapy. Therefore, routine CNS surveillance is not recommended among asymptomatic heritable RB survivors, regardless of prior radiation exposure.

Breast cancer

Evidence of risk: Yes

Grade of evidence for risk: A

Recommendation for surveillance: as per local guidelines

Sixteen studies, including 15 cohort analyses and one case-control study, examined risk of breast cancer among heritable and non-heritable RB survivors.^{22, 26–29, 32, 34, 39, 45–48, 53, 66, 70, 71} Modest evidence suggests that there may be an increased breast cancer risk among heritable RB survivors, with a standardized incidence ratio (SIR) of approximately 3.0-4.5. In most cases, breast cancer was diagnosed among women over the age of 40 years, as in the general population.⁷² No evidence to support early initiation of surveillance or expansion of existing screening programs for heritable RB survivors was identified. Therefore, the panel recommends that heritable RB survivors undergo surveillance for breast cancer as per local guidelines.

Based upon the association between therapeutic radiotherapy and SMN risk in RB survivors, there is an inferred or theoretical risk of ionizing radiation from diagnostic testing such as mammography. To date, no studies have quantified an incremental risk with diagnostic imaging that uses ionizing radiation among heritable RB survivors. Nevertheless, the panel was unanimous in recommending prioritization of non-radiation exposing imaging modalities, when possible.

Colon cancer

Evidence of risk: No

Grade of evidence for risk: A

Recommendation for surveillance: as per local guidelines

We reviewed results of 14 cohort studies that included cases of colorectal cancer among heritable RB survivors.^{22, 26–29, 32, 34, 35, 39, 45, 47, 53, 66, 73} While several cohorts include heritable RB survivors with colorectal cancer, adenocarcinoma cases were small in number (1–4 cases per publication) and at older age of onset (range 30–71.2 years).^{22, 28, 38, 39, 47, 53} In one cohort, two cases of gastrointestinal leiomyosarcoma were described.³² These tumors would not be expected to be amenable to surveillance practices and survival would not be impacted by surveillance for these tumors.^{74, 75} Therefore, while no increased risk of colorectal adenocarcinoma has been categorically identified in heritable RB survivors, ongoing observation is needed, possibly through the oversight of an international combined cohort study.

Hematologic malignancies

Evidence of risk: No

Grade of evidence for risk: A

Recommendation for surveillance: Recommendation not to do

With regards to risk of subsequent hematologic malignancies, primarily leukemia and lymphoma, we evaluated results from 19 cohort studies and one systematic review/meta-analysis.^{1, 14, 22, 26, 28, 29, 32–35, 37, 38, 45–47, 49, 50, 53, 66, 67} We found cases of Hodgkin lymphoma,²⁶ non-Hodgkin lymphoma,⁴⁷ acute lymphoblastic leukemia,^{1, 14} and acute myeloblastic leukemia.⁴⁵ Studies which included chemotherapy exposures described a known link between chemotherapy and therapy-related leukemia, usually related to delivery of an alkylating agent or an epipodophyllotoxin.⁵³ Existing protocols and guidelines call for surveillance for leukemia after treatment that includes these drugs;⁷⁶ no evidence for a long-term risk among heritable RB survivors that is *independent* of these known associations could be found. Therefore, additional surveillance for those without prior exposure to alkylating agents and/or epipodophyllotoxin is not recommended.

Lung cancer

Evidence of risk: Yes

Grade of evidence for risk: B

Recommendation: as per local guidelines

We reviewed 11 cohort studies and 1 systematic review/meta-analysis that included cases or deaths due to lung cancer among heritable RB survivors.^{22, 27, 32, 39, 45–47, 53, 66, 67, 77} Estimates of standardized mortality ratios ranged from 6.85 (95%CI: 2.75–14.1)⁴⁷ to 15.2 (95% CI: 4.9–35).⁷⁷ Unfortunately, many cohort studies lack data on smoking status, which may differ by heritable status.^{22, 47, 66, 78} In addition, some studies censored patients after the first subsequent malignant neoplasm, thereby reducing the chance of observing lung cancer cases, which are more likely to occur at an older age.^{22, 66} With evidence of uncertain or potentially biased results, lung cancer surveillance is not recommended for heritable RB survivors. RB survivors who have a history of smoking should be considered for surveillance

as per local recommendations.^{79,80} Future studies that include relevant tobacco exposures and allow for multiple subsequent malignant neoplasms in risk estimates are needed.

Melanoma

Evidence of risk: Yes

Grade of evidence for risk: A

Recommendation for surveillance: Strong recommendation to do (Table 1)

Modality: Single skin exam before age 8⁸¹ to identify those who are developing dysplastic nevi; annual skin exam with dermoscopy, where available, after adolescence; skin protection measures for survivors of all ages.

We reviewed 19 publications, including cohort studies from Germany, Italy, the Netherlands, the United Kingdom, and the United States. We found an increased risk of incident melanoma (SIR 18.6, 95% CI: 9.6-32.4)⁶⁶ as well as increased melanoma-related deaths (SMR 23.3- 89.0).^{22, 29} Evidence for a benefit of annual skin exams to prevent melanoma-related mortality is extrapolated from the literature from other high-risk populations as well as case-control and ecologic studies of population-based screening.^{82, 83} When melanoma cases within the US cohort were examined, many tumors were large and detected at a late stage, possibly related to decreased visual acuity in the RB survivor population. Therefore, patient education on skin protection measures and identification of nevi is suggested. Dysplastic nevi, when identified, should be carefully monitored and removed if changing in a manner suspicious for melanoma.⁸⁴

Thyroid cancer

Evidence of risk: No

Grade of evidence for risk: C

Recommendation for surveillance: Recommendation not to do

We found information about thyroid cancer occurrence among heritable RB survivors in 10 publications, including 9 cohort studies and 1 systematic review/meta-analysis.^{26-29, 44, 45, 48, 53, 66, 67} Among 953 heritable RB survivors representing 25,409 person-years of risk, two cases of thyroid cancer were observed, resulting in an SIR of 3.34 (95% CI: 0.4-12), which was not statistically significant.³² In a study of mortality risk among heritable RB survivors, no deaths from thyroid cancer were observed, although thyroid cancer is rarely fatal.²⁹ The existing evidence does not support an increased risk of thyroid cancer among RB survivors. Therefore, routine surveillance for thyroid cancer is not recommended in this population.

Uterine cancer

Evidence of risk: Yes

Grade of evidence for risk: A

Recommendation for surveillance: Recommendation not to do

Among the publications on SMN among heritable RB survivors, we found 12 that described uterine cancer, primarily uterine leiomyosarcoma.^{23, 24, 26–29, 32, 35, 47, 48, 66, 85} One paper, which specifically focused on uterine leiomyosarcoma,⁸⁵ described 7 cases of uterine leiomyosarcoma in a cohort of 525 heritable RB survivors, associated with 4 deaths and resulting in an SIR of 277 (95%CI: 90-646) and an absolute excess risk of 3.8/10000 person-years. An SMR of 154 (95%CI: 50-359) was reported for uterine cancer including leiomyosarcomas.²⁹ The ages of diagnosis of uterine leiomyosarcoma ranged from 32 to 51 years. Nonetheless, evidence for a benefit of current surveillance is not available and surveillance for uterine leiomyosarcoma is not recommended. While an increased risk is evident, especially of leiomyosarcoma of the uterus, no uterine imaging modality has been shown to be beneficial in this setting.⁸⁶

DISCUSSION

Adult survivors of heritable RB are at risk for developing SMN decades following diagnosis, especially sarcomas of bone and soft tissue, melanoma, and radiotherapy-related tumors. After a rigorous process of priority development and evidence review, we present the results regarding SMN surveillance of adult heritable RB survivors (Table 1). We recommend against surveillance in cases where risk is increased but current surveillance is not demonstrated to be beneficial, such as uterine leiomyosarcoma. We strongly support routine dermatologic surveillance in this population given the increased risk of melanoma, its relative ease of detection, and the potential lethality of melanoma when detected at later stages. We recommend prompt evaluation of concerning signs and symptoms, such as persistent sinusitis, pain, or skeletal tenderness. Although not reviewed specifically for this population, smoking prevention or cessation should be encouraged and supported in any healthcare setting.

While adult survivors of heritable RB are at increased risk for sarcomas of bone and soft tissue, the use of radiologic surveillance modalities such as whole body, head, or orbit MRI is not supported by the evidence. A recent meta-analysis suggests an emerging role for the use of whole-body MRI for SMN surveillance in other cancer predisposition syndromes.⁵⁹ We reviewed one case series describing 25 heritable RB survivors who underwent surveillance whole-body MRI. In that retrospective review, eight initial scans were abnormal and 2 osteosarcomas were detected. Both patients diagnosed with osteosarcoma died during the study period. An additional sarcoma was diagnosed three months after a normal whole-body MRI. Even in retrospect, the lesion was not visible on the scan.⁸⁷ Therefore, surveillance whole-body MRI provided no clear benefit. Given these findings as well as potential harms in this surveillance strategy, including cost, evaluation of incidental findings, and patient anxiety, our present recommendations do not support the use of MRI for sarcoma surveillance in heritable RB survivors. The need for prospective evaluation of a surveillance protocol, which may include whole body MRI, circulating cell-free (cf) DNA testing, skin exam with dermatoscope, or other modalities, is clear. Methods for early detection of uterine leiomyosarcoma, in which the case fatality rate is high and current methods of detection are inadequate, should be prioritized.

Ionizing radiation exposure is an established risk factor for numerous malignancies, with some evidence suggesting that risks are particularly high for individuals exposed at younger ages. Numerous studies have reported radiotherapy as a risk factor for subsequent neoplasms among heritable RB survivors, but there is limited evidence regarding whether this represents a sensitivity to the carcinogenic effects of ionizing radiation. Unfortunately, this question has not been addressed directly due to a paucity of studies of RB survivors with detailed data on radiation dose-response relations or genomic data.⁸⁸ Although some individuals may be radiosensitive,⁸⁹ such sensitivity has not been clearly demonstrated in the cancer predisposition syndromes such as Li-Fraumeni syndrome with germline *TP53* mutations.⁹⁰ Nevertheless, given the importance of retinoblastoma protein in cell cycle control and the high risk of radiotherapy - induced tumors in this population, minimizing exposure to ionizing radiation, as is currently recommended for individuals with Li-Fraumeni syndrome, is reasonable.^{59, 60}

The evidence review for this work involved multiple rigorous steps intended to strengthen the basis for the recommendations. Several country or region-specific heritable RB or cancer survivors cohorts were critical to this effort. Nonetheless, large-scale collaborative efforts with systematic, long-term follow-up of heritable RB survivors, which could include periodic protocol-guided imaging, are clearly needed. Inclusion of genetic data, as well as self-reported or objectively measured psychosocial, cognitive, and quality of life outcomes in these studies would be valuable; use of validated measures would be critical. Furthermore, our process did not include a patient representative or community stakeholder. We suggest that future efforts in understanding risk among the heritable RB populations incorporate international partners, patients, and family members to maximize overall impact as well as number of cases and heterogeneity of therapy. Finally, further characterization of potential differences in SMN risk by *RB1* mutation type and other genetic factors may enable more precise risk stratification and would impact calculations regarding potential benefit of surveillance or other risk-reducing strategies.

CONCLUSION

In conclusion, adult heritable RB survivors are a growing population at risk for SMNs, most notably uterine leiomyosarcoma, bone and soft tissue sarcoma, and melanoma. With the acknowledgement that no surveillance modality has been shown to extend life in this population, prompt evaluation of signs or symptoms and dermatologic evaluation in long-term follow-up is recommended.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements:

Funding: This work was supported in part by the National Institutes of Health, National Cancer Institute, Intramural Research Program and P30CA008748, and the Meg Berté Owen Fund. The funders had no role in the study design, data acquisition, analysis, manuscript preparation, or decision to submit this work.

Role of the funding source: The funding sources had no role in the data acquisition, analysis, manuscript preparation, or decision to submit this work. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

REFERENCES

1. Tamboli D, Topham A, Singh N, Singh AD. Retinoblastoma: A SEER Dataset Evaluation for Treatment Patterns, Survival, and Second Malignant Neoplasms. *Am J Ophthalmol* 2015;160(5):953–8. [PubMed: 26255575]
2. Abramson DH. Retinoblastoma: saving life with vision. *Annu Rev Med* 2014;65:171–84. [PubMed: 24422571]
3. MacCarthy A, Draper GJ, Steliarova-Foucher E, Kingston JE. Retinoblastoma incidence and survival in European children (1978-1997). Report from the Automated Childhood Cancer Information System project. *Eur J Cancer* 2006;42(13):2092–102. [PubMed: 16919773]
4. Lu JE, Francis JH, Dunkel IJ, et al. Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007–2017. *Br J Ophthalmol* 2018.
5. Abramson D, Ellsworth R, Zimmerman LJTSOAAoO, Otolaryngology. Nonocular cancer in retinoblastoma survivors. 1976;81(3 Pt 1):454–7.
6. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-term Follow-up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. *Journal of Clinical Oncology* 2004;22(24):4979–90. [PubMed: 15576413]
7. Oeffinger KC, Ford JS, Moskowitz CS, et al. Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study. *J Clin Oncol* 2019;37(24):2131–40. [PubMed: 31260642]
8. Turcotte LM, Neglia JP, Reulen RC, et al. Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review. *J Clin Oncol* 2018;36(21):2145–52. [PubMed: 29874133]
9. Steinberg E, Greenfield S, Wolman DM, et al. Clinical practice guidelines we can trust: National Academies Press, 2011.
10. Kremer LC, Mulder RL, Oeffinger KC, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Pediatric blood & cancer* 2013;60(4):543–9. [PubMed: 23281199]
11. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. *BMJ (Clinical research ed)* 2004;328(7454):1490–.
12. Children's Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers. 5.0 ed. 2018.
13. Pelizzari G, Arpino G, Biganzoli L, et al. An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. *BMC Cancer* 2018;18(1):932. [PubMed: 30261866]
14. Shinohara ET, DeWees T, Perkins SM. Subsequent malignancies and their effect on survival in patients with retinoblastoma. *Pediatr Blood Cancer* 2014;61(1):116–9. [PubMed: 23918737]
15. Hampshaw S, Cooke J, Mott L. What is a research derived actionable tool, and what factors should be considered in their development? A Delphi study. *BMC Health Serv Res* 2018;18(1):740. [PubMed: 30261925]
16. Prime SJ, Marchant J, Chang AB, Petsky HL. Development of a quality improvement audit tool for the primary care of children with chronic wet cough using a modified Delphi consensus approach. *J Paediatr Child Health* 2019;55(4):459–64. [PubMed: 30251373]
17. Provenzale D, Gupta S, Ahnen DJ, et al. NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. *J Natl Compr Canc Netw* 2018;16(8):939–49. [PubMed: 30099370]
18. Benson AB, Venook AP, Al-Hawary MM, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2018;16(7):874–901. [PubMed: 30006429]

19. Ettinger DS, Aisner DL, Wood DE, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. *J Natl Compr Canc Netw* 2018;16(7):807–21. [PubMed: 30006423]
20. Baker MS, McConnell LK, Kleinberg TT, et al. Orbital sarcomas in retinoblastoma patients: recommendations for screening and treatment guidelines. *Curr Opin Ophthalmol* 2016;27(5):443–8. [PubMed: 27213925]
21. Fidler MM, Reulen RC, Winter DL, et al. Risk of Subsequent Bone Cancers Among 69 460 Five-Year Survivors of Childhood and Adolescent Cancer in Europe. *J Natl Cancer Inst* 2018;110(2).
22. Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. *J Natl Cancer Inst* 2004;96(5):357–63. [PubMed: 14996857]
23. Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. *J Natl Cancer Inst* 2007;99(1):24–31. [PubMed: 17202110]
24. Kleinerman RA, Yu CL, Little MP, et al. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. *J Clin Oncol* 2012;30(9):950–7. [PubMed: 22355046]
25. Kleinerman RA, Schonfeld SJ, Tucker MA. Sarcomas in hereditary retinoblastoma. *Clin Sarcoma Res* 2012;2(1):15. [PubMed: 23036192]
26. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. *JAMA* 1997;278(15):1262–7. [PubMed: 9333268]
27. Wong JR, Morton LM, Tucker MA, et al. Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. *J Clin Oncol* 2014;32(29): 3284–90. [PubMed: 25185089]
28. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. *J Natl Cancer Inst* 1993;85(14):1121–8. [PubMed: 8320741]
29. Yu CL, Tucker MA, Abramson DH, et al. Cause-specific mortality in long-term survivors of retinoblastoma. *J Natl Cancer Inst* 2009;101(8):581–91. [PubMed: 19351917]
30. Chauveinc L, Mosseri V, Quintana E, et al. Osteosarcoma following retinoblastoma: age at onset and latency period. *Ophthalmic Genet* 2001 ;22(2):77–88. [PubMed: 11449317]
31. Koshy M, Paulino AC, Mai WY, Teh BS. Radiation-induced osteosarcomas in the pediatric population. *Int J Radiat Oncol Biol Phys* 2005;63(4):1169–74. [PubMed: 16054775]
32. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. *J Clin Oncol* 2005;23(10):2272–9. [PubMed: 15800318]
33. Temming P, Viehmann A, Arendt M, et al. Pediatric second primary malignancies after retinoblastoma treatment. *Pediatr Blood Cancer* 2015;62(10):1799–804. [PubMed: 25970657]
34. Acquaviva A, Ciccolallo L, Rondelli R, et al. Mortality from second tumour among long-term survivors of retinoblastoma: a retrospective analysis of the Italian retinoblastoma registry. *Oncogene* 2006;25(38):5350–7. [PubMed: 16936757]
35. Abramson DH, Melson MR, Dunkel IJ, Frank CM. Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. *Ophthalmology* 2001;108(10):1868–76. [PubMed: 11581064]
36. Aerts I, Pacquement H, Doz F, et al. Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie. *Eur J Cancer* 2004;40(10):1522–9. [PubMed: 15196536]
37. Araki Y, Matsuyama Y, Kobayashi Y, et al. Secondary neoplasms after retinoblastoma treatment: retrospective cohort study of 754 patients in Japan. *Jpn J Clin Oncol* 2011;41(3):373–9. [PubMed: 21051531]
38. DerKinderen DJ, Koten JW, Nagelkerke NJ, et al. Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. *Int J Cancer* 1988;41(4):499–504. [PubMed: 3356485]
39. Dommering CJ, Marees T, van der Hout AH, et al. RB1 mutations and second primary malignancies after hereditary retinoblastoma. *Fam Cancer* 2012;11(2):225–33. [PubMed: 22205104]
40. Dunkel IJ, Gerald wL, Rosenfield NS, et al. Outcome of patients with a history of bilateral retinoblastoma treated for a second malignancy: the Memorial Sloan-Kettering experience. *Med Pediatr Oncol* 1998;30(1):59–62. [PubMed: 9371391]

41. Friedman DN, Lis E, Sklar CA, et al. Whole-body magnetic resonance imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: a pilot study. *Pediatr Blood Cancer* 2014;61(8):1440–4. [PubMed: 24402721]
42. Fujiwara T, Fujiwara M, Numoto K, et al. Second primary osteosarcomas in patients with retinoblastoma. *Jpn J Clin Oncol* 2015;45(12):1139–45. [PubMed: 26438540]
43. Imhof SM, Moll AC, Hofman P, et al. Second primary tumours in hereditary- and nonhereditary retinoblastoma patients treated with megavoltage external beam irradiation. *Doc Ophthalmol* 1997;93(4):337–44. [PubMed: 9665291]
44. Kleinerman RA, Stovall M, Tarone RE, Tucker MA. Gene environment interactions in a cohort of irradiated retinoblastoma patients. *Radiat Res* 2005;163(6):701–2. [PubMed: 16044502]
45. MacCarthy A, Bayne AM, Draper GJ, et al. Non-ocular tumours following retinoblastoma in Great Britain 1951 to 2004. *Br J Ophthalmol* 2009;93(9): 1159–62. [PubMed: 19704040]
46. Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. *J Natl Cancer Inst* 2008;100(24):1771–9. [PubMed: 19066271]
47. Marees T, van Leeuwen FE, de Boer MR, et al. Cancer mortality in long-term survivors of retinoblastoma. *Eur J Cancer* 2009;45(18):3245–53. [PubMed: 19493675]
48. Mohny BG, Robertson DM, Schomberg PJ, Hodge DO. Second nonocular tumors in survivors of heritable retinoblastoma and prior radiation therapy. *Am J Ophthalmol* 1998;126(2):269–77. [PubMed: 9727521]
49. Moll AC, Imhof SM, Bouter LM, Tan KE. Second primary tumors in patients with retinoblastoma. A review of the literature. *Ophthalmic Genet* 1997;18(1):27–34. [PubMed: 9134547]
50. Roarty JD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. *Ophthalmology* 1988;95(11):1583–7. [PubMed: 3211467]
51. Schlienger P, Campana F, Vilcoq JR, et al. Nonocular second primary tumors after retinoblastoma: retrospective study of 111 patients treated by electron beam radiotherapy with or without TEM. *Am J Clin Oncol* 2004;27(4):411–9. [PubMed: 15289737]
52. Sethi RV, Shih HA, Yeap BY, et al. Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. *Cancer* 2014;120(1):126–33. [PubMed: 24122173]
53. Temming P, Arendt M, Viehmann A, et al. Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center. *Pediatr Blood Cancer* 2017;64(1):71–80. [PubMed: 27567086]
54. Moll AC, Imhof SM, Schouten-Van Meeteren AY, et al. Second primary tumors in hereditary retinoblastoma: a register-based study, 1945–1997: is there an age effect on radiation-related risk? *Ophthalmology* 2001;108(6):1109–14. [PubMed: 11382638]
55. Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. *Ophthalmology* 1998;105(4):573–9; discussion 9–80. [PubMed: 9544627]
56. Rodjan F, Graaf P, Brisse HJ, et al. Second cranio-facial malignancies in hereditary retinoblastoma survivors previously treated with radiation therapy: Clinic and radiologic characteristics and survival outcomes. *Eur J Cancer* 2013;49(8):1939–47. [PubMed: 23415887]
57. Mouw KW, Sethi RV, Yeap BY, et al. Proton radiation therapy for the treatment of retinoblastoma. *Int J Radiat Oncol Biol Phys* 2014;90(4):863–9. [PubMed: 25227498]
58. Anupindi SA, Bedoya MA, Lindell Rb, et al. Diagnostic Performance of Whole-Body MRI as a Tool for Cancer Screening in Children With Genetic Cancer-Predisposing Conditions. *AJR Am J Roentgenol* 2015;205(2):400–8. [PubMed: 26204294]
59. Ballinger ML, Best A, Mai PL, et al. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. *JAMA Oncol* 2017;3(12):1634–9. [PubMed: 28772291]
60. Mai PL, Khincha PP, Loud JT, et al. Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort. *JAMA Oncol* 2017;3(12):1640–5. [PubMed: 28772286]

61. Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. *Lancet Oncol* 2016;17(9):1295–305. [PubMed: 27501770]
62. Gulani V, Calamante F, Shellock FG, et al. Gadolinium deposition in the brain: summary of evidence and recommendations. *Lancet Neurol* 2017;16(7):564–70. [PubMed: 28653648]
63. McDonald JS, McDonald RJ, Jentoft ME, et al. Intracranial Gadolinium Deposition Following Gadodiamide-Enhanced Magnetic Resonance Imaging in Pediatric Patients: A Case-Control Study. *JAMA Pediatr* 2017;171(7):705–7. [PubMed: 28531274]
64. McBride KA, Ballinger ML, Schlub TE, et al. Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? *Fam Cancer* 2017;16(3):423–32. [PubMed: 28124295]
65. Kamihara J, Bourdeaut F, Foulkes WD, et al. Retinoblastoma and Neuroblastoma Predisposition and Surveillance. *Clin Cancer Res* 2017;23(13):e98–e106. [PubMed: 28674118]
66. Maccarthy A, Bayne AM, Brownbill PA, et al. Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951–2004. *Br J Cancer* 2013.
67. Woo KI, Harbour JW. Review of 676 second primary tumors in patients with retinoblastoma: association between age at onset and tumor type. *Arch Ophthalmol* 2010;128(7):865–70. [PubMed: 20625047]
68. Bowers DC, Moskowitz CS, Chou JF, et al. Morbidity and Mortality Associated With Meningioma After Cranial Radiotherapy: A Report From the Childhood Cancer Survivor Study. *J Clin Oncol* 2017;35(14):1570–6. [PubMed: 28339329]
69. Bowers DC, Nathan PC, Constine L, et al. Subsequent neoplasms of the CNS among survivors of childhood cancer: a systematic review. *Lancet Oncol* 2013;14(8):e321–8. [PubMed: 23816298]
70. Reulen RC, Taylor AJ, Winter DL, et al. Long-term population-based risks of breast cancer after childhood cancer. *Int J Cancer* 2008;123(9):2156–63. [PubMed: 18712734]
71. Little MP, Schaeffer ML, Reulen RC, et al. Breast cancer risk after radiotherapy for heritable and non-heritable retinoblastoma: a US-UK study. *Br J Cancer* 2014;110(10):2623–32. [PubMed: 24755883]
72. DeSantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. *CA: A Cancer Journal for Clinicians* 2017;67(6):439–48. [PubMed: 28972651]
73. Reulen RC, Frobisher C, Winter DL, et al. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. *JAMA* 2011;305(22):2311–9. [PubMed: 21642683]
74. Granero-Peiro L, Martinez-Ortega P, Sanchez-Justicia C, Hernandez-Lizoain JL. Leiomyosarcoma of the ascending colon: a rare tumor with poor prognosis. *Rev Esp Enferm Dig* 2015;107(9):584–5. [PubMed: 26334473]
75. Kono M, Tsuji N, Ozaki N, et al. Primary leiomyosarcoma of the colon. *Clin J Gastroenterol* 2015;8(4):217–22. [PubMed: 26208828]
76. Group CsO. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Survivors of Cancer. 2008; v. 2013.
77. Kleinerman RA, Tarone RE, Abramson DH, et al. Hereditary retinoblastoma and risk of lung cancer. *J Natl Cancer Inst* 2000;92(24):2037–9. [PubMed: 11121467]
78. Foster MC, Kleinerman RA, Abramson DH, et al. Tobacco use in adult long-term survivors of retinoblastoma. *Cancer Epidemiol Biomarkers Prev* 2006;15(8):1464–8. [PubMed: 16896033]
79. Smith RA, Andrews K, Brooks D, et al. Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA Cancer J Clin* 2016;66(2):95–114.
80. Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. *J Thorac Cardiovasc Surg* 2012;144(1):33–8. [PubMed: 22710039]
81. Tucker MA, Greene MH, Clark WH, Jr., et al. Dysplastic nevi on the scalp of prepubertal children from melanoma-prone families. *J Pediatr* 1983;103(1):65–9. [PubMed: 6864397]
82. Wernli KJ, Henrikson NB, Morrison CC, et al. Screening for skin cancer in adults: Updated evidence report and systematic review for the us preventive services task force. *JAMA* 2016;316(4):436–47. [PubMed: 27458949]

83. Soura E, Eliades PJ, Shannon K, et al. Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. *J Am Acad Dermatol* 2016;74(3):395–407; quiz 8-10. [PubMed: 26892650]
84. Goldstein AM, Tucker MA. Dysplastic nevi and melanoma. *Cancer Epidemiol Biomarkers Prev* 2013;22(4):528–32. [PubMed: 23549396]
85. Francis JH, Kleinerman RA, Seddon JM, Abramson DH. Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma. *Gynecol Oncol* 2012;124(2):254–9. [PubMed: 22027510]
86. Van den Bosch T, Coosemans A, Morina M, et al. Screening for uterine tumours. *Best Pract Res Clin Obstet Gynaecol* 2012;26(2):257–66. [PubMed: 22078749]
87. Benedict C, Thom B, Friedman DN, et al. Late Toxicities of Intensity-Modulated Radiation Therapy for Head and Neck Rhabdomyosarcoma. *Cancer* 2016.
88. Berrington de Gonzalez A, Gilbert E, Curtis R, et al. Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. *Int J Radiat Oncol Biol Phys* 2013;86(2):224–33. [PubMed: 23102695]
89. West CM, Barnett GC. Genetics and genomics of radiotherapy toxicity: towards prediction. *Genome Med* 2011;3(8):52. [PubMed: 21861849]
90. Little JB, Nove J. Sensitivity of human diploid fibroblast cell strains from various genetic disorders to acute and protracted radiation exposure. *Radiat Res* 1990;123(1):87–92. [PubMed: 2371384]

Table 1.

Summary of recommendations for SMN surveillance of heritable RB survivors.

What subsequent malignant neoplasms are heritable RB survivors at risk for?
<p>Strong evidence of risk:</p> <ul style="list-style-type: none"> • Bone and soft tissue sarcoma • Melanoma • Uterine leiomyosarcoma <p>Strong evidence of risk which may be limited to those with a history of radiotherapy:</p> <ul style="list-style-type: none"> • Brain and central nervous system tumors <p>Moderate evidence of risk:</p> <ul style="list-style-type: none"> • Breast cancer after the age of 40 years • Lung cancer <p>No or low evidence of risk:</p> <ul style="list-style-type: none"> • Gastrointestinal malignancies, including colon cancer • Hematologic malignancies, apart from those attributable to systemic chemotherapy • Thyroid cancer
What surveillance is recommended for heritable RB survivors?
<p>Strong recommendation to do:</p> <ul style="list-style-type: none"> • Annual skin examination, especially among those with dysplastic nevi. <p>Moderate recommendation to do:</p> <ul style="list-style-type: none"> • Annual history and physical exam with attention to bony structures. • Prompt evaluation of signs and symptoms such as persistent sinusitis, pain, or skeletal tenderness. <p>Weak recommendation to do:</p> <ul style="list-style-type: none"> • Consideration should be given in favor of surveillance modalities that do not include ionizing radiation, although evidence for or against this recommendation in heritable RB survivors is lacking. <p>Recommendation not to do:</p> <ul style="list-style-type: none"> • We do not recommend surveillance for uterine leiomyosarcoma, as surveillance is not likely to be beneficial and may result in harm. • We do not recommend annual thyroid ultrasound for thyroid cancer surveillance, as there is no clear increased risk in this population. Furthermore, surveillance is not likely to benefit thyroid cancer-related mortality and may result in harm. • We do not recommend additional surveillance (beyond what is recommended based on local guidelines) for bone, brain, breast, colorectal, hematologic, or lung cancers, where risk is uncertain or benefit cannot be anticipated.